Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT04012710
Starting soon Not applicable

vNOTES for Salpingo-oophorectomy

NCT04012710 · tracked via the Priya Life Science Israel tracker
Sponsor
Sheba Medical Center
Phase
Not applicable
Started
2025-07-03
Last updated
2024-11-14

Condition(s) studied

Surgery

Investigational drug(s) / intervention(s)

LaparoscopyvNOTES

Laparoscopy: Conventional abdominal laparoscopy

vNOTES: Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy

Study summary

The aim of this study is to compare the common approach of laparoscopy for bilateral salpingo - oophorectomy to a new approach via transvaginal natural orifice transluminal endoscopic surgery (vNOTES).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Elective surgery * Benign indication for surgery Exclusion Criteria: * Severe endometriosis * Past pelvic operations * Suspected malignancy * Combined planned hysterectomy * Recurrent Pelvic Inflammatory disease (PID) * Vaginal anomaly

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Aya Mohr Sasson Ramat Gan Please Select

More Sheba Medical Center trials in Israel

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer Recruiting
Clemastine Treatment in Individuals With Williams Syndrome Active, not recruiting
Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury Recruiting
Hepatopulmonary Radio-sterilization With Immunotherapy Starting soon
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study Enrolling by invitation

Other trials for the same condition

Multicenter Phase II Study of Transanal TME (taTME) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04012710 on ClinicalTrials.gov ↗ ← All trials in Israel